Fingerprint authentication used to prevent dual enrollment in clinical trials
Celerion has implemented Verified Clinical Trials (VCT) biometric fingerprint technology to identify participants that are currently enrolled in other clinical studies.
VCT’s biometric fingerprint technology will augment the accuracy and speed of the verifications performed at Celerion facilities utilizing the VCT global clinical database registry.
“Our focus has always been to help our clients get their drugs to market and protect the safety and well-being of our participants. The VCT database registry enhances our ability to achieve both of those objectives,” said Phil Bach, Vice President, Global Clinical Research, Celerion. “Celerion and VCT share the same vision of applying scientific expertise and advanced technology to ensure the safety of our participants and maintain data integrity leading to successful clinical trial outcomes.”
The quality of data in a clinical trial could be compromised by subjects of a trial participating in other ones without disclosing that information.
“Following Celerion’s lead, the majority of Phase I units across North America now utilize the VCT system every day to protect their clinical trials. VCT offers the most comprehensive and unique clinical research subject database registry to enhance the quality of both early and late stage studies globally. The system provides a level of safety to the clinical trial process that could not be attained without a solution like VCT,” said Mitchell Efros, MD FACS, CEO at VCT.
Just last month, High Point Clinical Trials Center announced that it had partnered with VCT to launch early and late-phase trials of a fingerprint registration system to prevent duplicate enrollment in clinical trials.